RxDoctor Payments Data

Kenneth Ryder, MD

Family Medicine · Schnecksville, PANPI 1588616429

Payments from drug & device makers

$3,599in general payments, 2019–2025

Across 177 payments — averaging $20.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$531
  • Biohaven Pharmaceuticals, Inc.$391
  • Lilly USA, LLC$342
  • Boehringer Ingelheim$329
  • AstraZeneca$302
  • Abbott$177
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$3,599100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,599 in reported general payments places this provider in the 80th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$82,603
Medicare patients
240
Services billed
2,100

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide82$78,129
RinvoqUpadacitinib12$75,631
JardianceEmpagliflozin58$67,688
EliquisApixaban47$59,172
OzempicSemaglutide28$35,451
Tresiba Flextouch U-200Insulin Degludec15$25,650
Janumet XrSitagliptin Phos/Metformin Hcl22$23,907
MyrbetriqMirabegron15$15,795
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$8,615
Testosterone16$3,984
PremproEstrogen,con/M-Progest Acet13$3,157
Doxazosin Mesylate98$2,278
Losartan Potassium176$2,194
Atorvastatin Calcium251$2,131
Ezetimibe47$1,851

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$342$78,12982 claims
AbbVieRinvoq$175$75,63112 claims
Boehringer IngelheimJardiance$329$67,68858 claims
PfizerEliquis, Prempro$81$62,32960 claims
Novo NordiskOzempic$531$35,45128 claims
MerckJanumet Xr$91$23,90722 claims
Astellas Pharma US IncMyrbetriq$146$15,79515 claims
GSKTrelegy Ellipta$107$8,61515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Schnecksville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →